Targeted therapy for BRAF positive melanoma uses medicines designed to block abnormal signals that help cancer cells grow. These treatments may be considered for people whose melanoma contains specific BRAF gene changes. Understanding available therapies, treatment combinations, possible side effects, and monitoring requirements helps patients learn about their treatment options. Treatment decisions depend on cancer stage, overall health.
Melanoma is a type of skin cancer that develops from melanocytes, the cells responsible for producing pigment. Some melanomas contain changes in the BRAF gene, particularly the V600E or V600K mutations. These changes can activate signaling pathways that encourage cancer cells to grow and divide. Targeted therapy focuses on blocking these signals and may be used for certain patients with BRAF mutation positive melanoma.
Targeted therapy uses medicines that act on specific molecules involved in cancer growth. In BRAF mutated melanoma, treatment commonly targets the BRAF protein and the MEK protein, which are part of the MAPK signaling pathway. Blocking these proteins can reduce cancer cell growth and, in some cases, shrink tumors.
Before treatment, doctors generally use molecular testing to determine whether a melanoma contains an actionable BRAF mutation. The results, cancer stage, previous treatments, and overall health help guide treatment selection.
Common targeted therapy combinations include:
Dabrafenib and trametinib: Dabrafenib inhibits the abnormal BRAF protein, while trametinib blocks MEK activity. The combination may be used for eligible patients with BRAF V600 mutation positive melanoma.
Vemurafenib and cobimetinib: Vemurafenib targets the altered BRAF protein, while cobimetinib inhibits MEK. This combination is another option for certain patients.
Encorafenib and binimetinib: Encorafenib blocks BRAF activity, and binimetinib targets MEK. Together, they can interfere with signals that support melanoma growth.
These combinations are used in appropriate clinical settings, including certain cases of unresectable or metastatic melanoma. Some may also be considered after surgery in eligible patients to reduce the risk of recurrence.
Targeted therapy can produce relatively rapid tumor responses in some people with BRAF mutated melanoma. Combining BRAF and MEK inhibitors generally improves treatment outcomes compared with using a BRAF inhibitor alone and can reduce certain resistance-related problems. However, the response varies between individuals, and cancer can eventually develop resistance to treatment.
Treatment requires regular medical supervision because these medicines can affect several organs and body systems. Doctors evaluate potential benefits alongside the patient's medical history and other treatment options.
Important considerations include:
Common side effects: Fever, fatigue, nausea, diarrhea, skin reactions, joint pain, and rash may occur, depending on the medicines used.
Potential serious effects: Certain treatments can cause heart problems, eye complications, liver abnormalities, bleeding, or severe skin reactions. The specific risks vary by drug combination.
Regular monitoring: Medical teams may recommend blood tests, skin examinations, heart assessments, eye evaluations, and other checks based on the treatment prescribed.
Treatment resistance: Some melanomas stop responding over time. Doctors may reassess the cancer and consider other treatments, including immunotherapy or clinical trials.
Individualized treatment planning: Cancer stage, previous therapy, mutation type, coexisting medical conditions, and personal preferences influence treatment decisions.
Patients should report new or worsening symptoms to their healthcare team promptly. Fever, breathing difficulties, severe abdominal symptoms, vision changes, or other serious symptoms may require urgent medical assessment. Patients should not change doses or discontinue prescribed medicines without discussing the decision with their treating team.
Understanding targeted therapy helps patients participate in informed discussions with their oncologists. Molecular testing, appropriate treatment selection, and ongoing monitoring are important parts of managing BRAF positive melanoma. The most suitable approach depends on individual circumstances, and treatment options should be discussed with a qualified oncology professional.